InnoLAMP TECHNOLOGY

G2GBIO developed a proprietary technology named InnoLAMP (Innovative Long-Acting Microsphere Platform) that overcomes the limitations of conventional manufacturing methods. Using InnoLAMP, G2GBio succeeded in producing competitive microspheres.

InnoLAMP (Innovative Long-Acting Microsphere Platform)
Principle of Drug Sustainability

Drug-release sustained after administration for one to over six months

Technology for uniform microsphere manufacturing & mass production

Particle size control
Primary determination based on the pore size of the membrane
GMP-compliant High Scale-up
Easy scale-up to manufacture up to several kilograms per hour
Technology for uniform microsphere manufacturing & mass production

Pilot Manufacturing facility

capable of producing 10-30 kg of pharmaceuticals

Uniform production of microspheres in various sizes
InnoLAMP facilitates mass production of homogenous microspheres
and enables speedy production of highly soluble drugs such as peptides.

InnoLAMP (Innovative Long-Acting Microsphere Platform)

Property
G2GBIO's technology involves the production of uniform microspheres (10~100μm) by encapsulating drugs with biodegradable polymers
Effect
The drug is sustainably released over a period of one week to several months, allowing for long-lasting effects of the drug.
Strength of InnoLAMP
Precise size & release control
The uniform production of microspheres and precise control over their release profile
Easy Scale-Up
Easier scale-up and sterile GMP production compared to the conventional technologies
Diverse Applications
Application in various diseases with unmet medical needs in terms of drug sustainability and medication adherence
InnoLAMP's manufacturing method based on membrane emulsification
Simplification of the existing production process and optimization of sterile GMP production of pharmaceuticals

InteLAMP TECHNOLOGY

It facilitates not only sustained release of drugs from microspheres but also uniform distribution of microspheres within the tumor tissue to selectively kill cancer cells

InteLAMP (Intelligent Local-Acting Microsphere Platform) Principle and Technology Differentiation

Customized sustained-release microsphere treatments can be developed using InteLAMP technology
Improved distribution of microspheres within tumors

[References]
1. Nature Reviews Clinical Oncology / Intratumoural administration and tumour tissue targeting of cancer immunotherapies / Ignacio Melero, Eduardo Castanon, Maite Alvarez, Stephane Champiat & Aurelien Marabelle / Published: 18 May 2021